AusperBio to Present Two Posters on AHB-137, a Novel Antisense Oligonucleotide for Hepatitis B at EASL™ Congress 2023

Posted on by

Data will highlight the preclinical antiviral activity, pharmacokinetic property, and safety profile of AHB-137, a potential best-in-class antisense oligonucleotide (ASO) for the treatment of chronic Hepatitis B (CHB). SAN FRANCISCO, June 12, 2023 /PRNewswire/ — Ausper Biopharma Co., Ltd….

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.